On May 8, 2025, renowned financial services firm Oppenheimer initiated coverage on InflaRx (IFRX, Financial), a biotechnology company, with an "Outperform" rating. The coverage was announced by analyst Andreas Argyrides.
The current price target set by Oppenheimer for InflaRx (IFRX, Financial) is $6.00 USD. This marks the first coverage initiation for InflaRx by Oppenheimer, as there was no previously established price target.
InflaRx (IFRX, Financial) is primarily listed on the NASDAQ exchange and has gained attention in the market due to its innovative approaches in immunology and inflammation sector.
Investors and stakeholders are advised to keep an eye on updates from Oppenheimer regarding InflaRx (IFRX, Financial) as the "Outperform" rating suggests a positive outlook on the company's potential market performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for InflaRx NV (IFRX, Financial) is $9.34 with a high estimate of $13.01 and a low estimate of $5.00. The average target implies an upside of 531.13% from the current price of $1.48. More detailed estimate data can be found on the InflaRx NV (IFRX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, InflaRx NV's (IFRX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
